FI970565A0 - HIV proteasinhibitorkombination - Google Patents

HIV proteasinhibitorkombination

Info

Publication number
FI970565A0
FI970565A0 FI970565A FI970565A FI970565A0 FI 970565 A0 FI970565 A0 FI 970565A0 FI 970565 A FI970565 A FI 970565A FI 970565 A FI970565 A FI 970565A FI 970565 A0 FI970565 A0 FI 970565A0
Authority
FI
Finland
Prior art keywords
hiv
hiv protease
proteasinhibitorkombination
treatment
methods
Prior art date
Application number
FI970565A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI970565A (en
Inventor
Paul J Deutsch
Emilio A Emini
Joseph P Vacca
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of FI970565A0 publication Critical patent/FI970565A0/en
Publication of FI970565A publication Critical patent/FI970565A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The combination of the HIV protease inhibitor Compound J and any one or more of four other potent HIV protease inhibitors is useful in the inhibition of HIV protease, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
FI970565A 1994-08-11 1997-02-10 HIV protease inhibitory combination FI970565A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28947494A 1994-08-11 1994-08-11
US33936994A 1994-11-14 1994-11-14
US49246195A 1995-07-20 1995-07-20
PCT/US1995/009956 WO1996004913A1 (en) 1994-08-11 1995-08-07 Hiv protease inhibitor combination

Publications (2)

Publication Number Publication Date
FI970565A0 true FI970565A0 (en) 1997-02-10
FI970565A FI970565A (en) 1997-02-10

Family

ID=27403895

Family Applications (1)

Application Number Title Priority Date Filing Date
FI970565A FI970565A (en) 1994-08-11 1997-02-10 HIV protease inhibitory combination

Country Status (20)

Country Link
EP (1) EP0774969B8 (en)
JP (1) JPH10504036A (en)
KR (1) KR970704441A (en)
CN (1) CN1101190C (en)
AT (1) ATE232727T1 (en)
AU (1) AU698664B2 (en)
CA (1) CA2197207C (en)
CY (1) CY2360B1 (en)
CZ (1) CZ292577B6 (en)
DE (1) DE69529678T2 (en)
DK (1) DK0774969T3 (en)
ES (1) ES2190456T3 (en)
FI (1) FI970565A (en)
HU (1) HUT76540A (en)
IL (1) IL114808A (en)
MX (1) MX9701121A (en)
NO (1) NO314168B1 (en)
PL (1) PL181578B1 (en)
SK (1) SK18197A3 (en)
WO (1) WO1996004913A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA49803C2 (en) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Method for treatment of retrovirus infections
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
AU716760B2 (en) * 1996-11-08 2000-03-09 Japan Energy Corporation Aids therapeutic composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US517041A (en) * 1894-03-27 Fruit-picker
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
HU9301446D0 (en) * 1990-11-19 1993-11-29 Monsanto Co Inhibitors or fetrovirus protease
ES2151618T3 (en) * 1990-11-19 2001-01-01 Monsanto Co INHIBITORS OF RETROVIRAL PROTEASES.
IE20010533A1 (en) * 1990-11-20 2003-03-05 Abbott Lab Intermediates for preparing retroviral protease inhibiting compounds
DK0541168T3 (en) * 1991-11-08 1998-05-11 Merck & Co Inc HIV protease inhibitors suitable for the treatment of AIDS
DK0727419T3 (en) * 1992-12-29 2002-06-10 Abbott Lab Intermediates for the preparation of compounds that inhibit retroviral protease

Also Published As

Publication number Publication date
DK0774969T3 (en) 2003-03-31
PL181578B1 (en) 2001-08-31
DE69529678D1 (en) 2003-03-27
MX9701121A (en) 1997-05-31
IL114808A (en) 1999-10-28
NO314168B1 (en) 2003-02-10
PL318506A1 (en) 1997-06-23
CZ292577B6 (en) 2003-10-15
EP0774969B1 (en) 2003-02-19
EP0774969B8 (en) 2003-07-02
AU698664B2 (en) 1998-11-05
ES2190456T3 (en) 2003-08-01
CZ38997A3 (en) 1997-11-12
JPH10504036A (en) 1998-04-14
HUT76540A (en) 1997-09-29
CY2360B1 (en) 2004-06-04
CA2197207C (en) 2006-10-17
CA2197207A1 (en) 1996-02-22
FI970565A (en) 1997-02-10
NO970632D0 (en) 1997-02-11
ATE232727T1 (en) 2003-03-15
SK18197A3 (en) 1997-09-10
DE69529678T2 (en) 2003-09-25
KR970704441A (en) 1997-09-06
WO1996004913A1 (en) 1996-02-22
CN1160350A (en) 1997-09-24
EP0774969A1 (en) 1997-05-28
NO970632L (en) 1997-04-10
AU3361195A (en) 1996-03-07
CN1101190C (en) 2003-02-12
IL114808A0 (en) 1995-12-08

Similar Documents

Publication Publication Date Title
ATE175412T1 (en) HIV PROTEASE INHIBITORS
ATE377011T1 (en) GAMMA-HYDROXY-2-(FLUORALKYLAMINOCARBONYL)-1-PIPERAZINE PENTANAMIDE AS AN HIV PROTEASE INHIBITOR
MY109834A (en) Benzoxazinones as inhibitors of hiv reverse transcriptase
DE69531944D1 (en) NEW HIV PROTEASE INHIBITORS
ATE215952T1 (en) HIV PROTEASE INHIBITORS
MX9705916A (en) Combination therapy for hiv infection using the hiv protease inhibitor indinavir adn the reverse transcriptase inhibitor 3tc, optionally together with azt, ddi or ddc.
MX9700036A (en) Combination therapy for hiv infection.
DK0774969T3 (en) HIV protease inhibitor combination
WO2002096359A3 (en) Piperazine pentanamide hiv protease inhibitors

Legal Events

Date Code Title Description
FD Application lapsed